

XTL BIOPHARMACEUTICALS LTD

Form 6-K

October 03, 2013

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16**

**of the Securities Exchange Act of 1934**

For the month of September, 2013

Commission File Number: **000-51310**

**XTL Biopharmaceuticals Ltd.**

(Translation of registrant's name into English)

**85 Medinat Hayehudim St., Herzliya  
Pituach, PO Box 4033,**

**Herzliya 4614001, Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A

**Incorporation by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated October 3, 2013 is hereby incorporated by reference into the registration statements on Form S-8 (File No. 333-148085, File No. 333-148754 and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on December 14, 2007, January 18, 2008, and October 28, 2008, respectively.**

On October 1, 2013, XTL Biopharmaceuticals Ltd. (the “*Company*”) filed a 6-K announcing an aggregate sale of treasury shares by the Company’s subsidiary, Intercure Ltd. (the “*Original 6-K*”).

The Company hereby expands upon the details of these sales and the changes in treasury share holdings reported in the Original 6-K, as required by TASE, with the following supplement:

**Treasury shareholder:** InterCure Ltd.

**Type of shareholder:** Company Subsidiary

<b>Type of change</b>	<b>Date of transaction</b>	<b>Quoted price (NIS)</b>	<b>Holding in treasury shares prior to change</b>	<b>Change in share quantity</b>	<b>Holding in treasury shares after change</b>	<b>Percent of holding in Company equity after change</b>
Sale	09/01/2013	1.094	6,949,053	27,000	6,922,053	2.97%
Sale	09/02/2013	1.078	6,922,053	2,253	6,919,800	2.97%
Sale	09/03/2013	1.0864	6,919,800	6,608	6,913,192	2.97%
Sale	09/10/2013	1.066	6,913,192	8,083	6,905,109	2.97%
Sale	09/11/2013	1.06	6,905,109	22,598	6,882,511	2.96%
Sale	09/12/2013	1.0596	6,882,511	45,328	6,837,183	2.94%
Sale	09/15/2013	1.097	6,837,183	15,000	6,822,183	2.93%
Sale	09/23/2013	1.014	6,822,183	8,818	6,813,365	2.93%

Please note that the sales listed above were executed by a trustee in accordance with a blind trust agreement.



**About XTL Biopharmaceuticals Ltd. (“XTL”)**

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. XTL is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C.

XTL’s lead drug candidate, rHuEPO, for the treatment of multiple myeloma blood cancer, was granted an orphan drug designation from the FDA. rHuEPO has been approved for marketing by the FDA and has for many years been sold for billions of dollars across the world for the treatment of severe anemia.

XTL controls InterCure Ltd. (TASE: INCR), a company which has disrupted the \$42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device, RESPeRATE® ([www.resperate.com](http://www.resperate.com)).

XTL is a public company traded on the NASDAQ Stock Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTL). XTL shares are included in the following indices: Tel-Aviv MidCap-50, Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Bluetech-50.

Contact:

Investor Relations, XTL Biopharmaceuticals Ltd.

Tel: +972 9 955 7080, Email: [ir@xtlbio.com](mailto:ir@xtlbio.com), [www.xtlbio.com](http://www.xtlbio.com)

Contact:

Investor Relations, XTL Biopharmaceuticals Ltd.

Tel: +972 9 955 7080, Email: [ir@xtlbio.com](mailto:ir@xtlbio.com)

### **Cautionary Statement**

Some of the statements included in this Form 6-K may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

- 4 -

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**XTL BIOPHARMACEUTICALS  
LTD.**

Date: October 3, 2013 By: /s/ David Grossman  
David Grossman  
Chief Executive Officer